540 related articles for article (PubMed ID: 16650951)
101. Evaluation of antimicrobial activity of beta-lactam antibiotics by Etest against clinical isolates from 100 medical centers in Japan (2004).
Ishii Y; Alba J; Kimura S; Yamaguchi K
Diagn Microbiol Infect Dis; 2006 Jun; 55(2):143-8. PubMed ID: 16529905
[TBL] [Abstract][Full Text] [Related]
102. Surveillance of antimicrobial resistance in gram-negative isolates from intensive care units in Turkey: analysis of data from the last 5 years.
Leblebicioglu H; Gunaydin M; Esen S; Tuncer I; Findik D; Ural O; Saltoslu N; Yaman A; Tasova Y;
J Chemother; 2002 Apr; 14(2):140-6. PubMed ID: 12017368
[TBL] [Abstract][Full Text] [Related]
103. Belgian multicentre study on the in vitro activity of cefepime against gram-negative bacilli.
Verbist L; Glupczynski Y
Acta Clin Belg; 1996; 51(1):28-35. PubMed ID: 8669160
[TBL] [Abstract][Full Text] [Related]
104. In vitro activity of fosfomycin-gentamicin, fosfomycin-ceftazidime, fosfomycin-imipenem and ceftazidime-gentamicin combinations against ceftazidime-resistant Pseudomonas aeruginosa.
Pruekprasert P; Tunyapanit W
Southeast Asian J Trop Med Public Health; 2005 Sep; 36(5):1239-42. PubMed ID: 16438151
[TBL] [Abstract][Full Text] [Related]
105. In-vitro activity of cefepime and other broad-spectrum antimicrobials against several groups of gram-negative bacilli and Staphylococcus aureus.
Tallis E; Rudensky B; Attias D; Raveh D; Schlesinger Y; Yinnon AM
Diagn Microbiol Infect Dis; 1999 Oct; 35(2):121-6. PubMed ID: 10579092
[TBL] [Abstract][Full Text] [Related]
106. In vitro evaluation of broad-spectrum beta-lactams tested in medical centers in Korea: role of fourth-generation cephalosporins. The Korean Antimicrobial Resistance Study Group.
Lewis MT; Biedenbach DJ; Jones RN
Diagn Microbiol Infect Dis; 1999 Dec; 35(4):317-23. PubMed ID: 10668591
[TBL] [Abstract][Full Text] [Related]
107. Antimicrobial activities of doripenem and other carbapenems against Pseudomonas aeruginosa, other nonfermentative bacilli, and Aeromonas spp.
Castanheira M; Jones RN; Livermore DM
Diagn Microbiol Infect Dis; 2009 Apr; 63(4):426-33. PubMed ID: 19249180
[TBL] [Abstract][Full Text] [Related]
108. Comparison of the double-disk, combined disk, and Etest methods for detecting metallo-beta-lactamases in gram-negative bacilli.
Yan JJ; Wu JJ; Tsai SH; Chuang CL
Diagn Microbiol Infect Dis; 2004 May; 49(1):5-11. PubMed ID: 15135493
[TBL] [Abstract][Full Text] [Related]
109. Activity of cefepime against ceftazidime-resistant gram-negative bacilli using low and high inocula.
Johnson CC; Livornese L; Gold MJ; Pitsakis PG; Taylor S; Levison ME
J Antimicrob Chemother; 1995 Jun; 35(6):765-73. PubMed ID: 7559188
[TBL] [Abstract][Full Text] [Related]
110. Antimicrobial activity of FK-037, a new broad-spectrum cephalosporin. International in vitro comparison with cefepime and ceftazidime.
Frei R; Jones RN; Pignatari AC; Yamane N; Marco F; Hoban DJ
Diagn Microbiol Infect Dis; 1994 Mar; 18(3):167-73. PubMed ID: 7924209
[TBL] [Abstract][Full Text] [Related]
111. Bacteraemia in Europe--antimicrobial susceptibility data from the MYSTIC surveillance programme.
Unal S; Masterton R; Goossens H
Int J Antimicrob Agents; 2004 Feb; 23(2):155-63. PubMed ID: 15013041
[TBL] [Abstract][Full Text] [Related]
112. Comparative in vitro activity of piperacillin/tazobactam against gram-negative bacilli.
Liebowitz LD; Klugman KP
S Afr Med J; 1996 Oct; 86(10):1276-80. PubMed ID: 8955735
[TBL] [Abstract][Full Text] [Related]
113. Susceptibility of Xanthomonas maltophilia and amikacin-resistant gram-negative bacteria to newer antimicrobials.
Matsuyama JR; Beail B; Wallis C; Zeleznik D; Tartaglione T
Clin Pharm; 1991 Jul; 10(7):544-8. PubMed ID: 1860303
[TBL] [Abstract][Full Text] [Related]
114. A comparative study of the in-vitro activity of cefepime and other cephalosporins.
Lim VK; Halijah MY
Malays J Pathol; 1993 Jun; 15(1):65-8. PubMed ID: 8277793
[TBL] [Abstract][Full Text] [Related]
115. Evaluation of VITEK 2 rapid identification and susceptibility testing system against gram-negative clinical isolates.
Ling TK; Tam PC; Liu ZK; Cheng AF
J Clin Microbiol; 2001 Aug; 39(8):2964-6. PubMed ID: 11474023
[TBL] [Abstract][Full Text] [Related]
116. Characteristics of pathogens causing urinary tract infections in hospitals in North America: results from the SENTRY Antimicrobial Surveillance Program, 1997.
Jones RN; Kugler KC; Pfaller MA; Winokur PL
Diagn Microbiol Infect Dis; 1999 Sep; 35(1):55-63. PubMed ID: 10529882
[TBL] [Abstract][Full Text] [Related]
117. Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina.
Fernández Canigia L; Kaufman S; Lanata L; Vay C; Giovanakis M; Bantar C;
Chemotherapy; 2009; 55(1):20-7. PubMed ID: 18974645
[TBL] [Abstract][Full Text] [Related]
118. [Antimicrobial resistance of Gram-negative bacilli isolated from patients in intensive care unit].
Huang X; Xu XH; Wen XM; Huang X; Li J; Wu AH
Zhongguo Wei Zhong Bing Ji Jiu Yi Xue; 2005 Jul; 17(7):409-11. PubMed ID: 16004780
[TBL] [Abstract][Full Text] [Related]
119. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
[TBL] [Abstract][Full Text] [Related]
120. Activity of cefepime compared with other antibiotics against gram-positive bacteria and cefuroxime-resistant gram-negative bacteria.
Wang FD; Liu IM; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):408-13. PubMed ID: 9699393
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
